Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 19/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 2/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inogatran SCHEMBL1208039 | 0.87 | F2 (0.52) | F2PRSS1F10PLGPLAT | |
| Inogatran SCHEMBL22746 | 0.87 | F2 (0.52) | F2PRSS1F10PLGPLAT | |
| Inogatran SCHEMBL22745 | 0.87 | F2 (0.52) | F2PRSS1F10PLGPLAT | |
| Inogatran SCHEMBL6666022 | 0.86 | F2 (0.51) | F2PRSS1F10PLGPLAT | |
| SCHEMBL8409263 | 0.85 | F2 (0.45) | F2PRSS1F10PLGPLAT | |
| SCHEMBL14082058 | 0.76 | F2 (0.62) | F2PRSS1F10PLGPLAT | |
| SCHEMBL6665350 | 0.73 | PRCP (0.45) | F2PRSS1F10PLG | |
| SCHEMBL23793969 | 0.70 | F2 (0.75) | F2PRSS1F10PLGPLAT | |
| SCHEMBL24322805 | 0.69 | F2 (0.52) | F2 | |
| SCHEMBL13141165 | 0.69 | F2 (0.47) | F2PRSS1F10PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | F2 107/4885PRSS1 545/4885F10 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.